Simultaneous Occurrence of Germline Mutations of SDHB and TP53 in a Patient with Metastatic Pheochromocytoma

被引:10
|
作者
Gniado, Ewa [1 ]
Carracher, Colin P. [1 ]
Sharma, Sona [1 ]
机构
[1] Univ Cincinnati, Div Endocrinol Diabet & Metab, Cincinnati, OH 45229 USA
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2020年 / 105卷 / 04期
关键词
metastatic pheochromocytoma; SDHB mutation; TP53; mutation; MALIGNANT PHEOCHROMOCYTOMA;
D O I
10.1210/clinem/dgz269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context. We describe a patient with metastatic malignant pheochromocytoma who was found to have germline SDHB and TP53 mutations occurring together. Case Description. A 39-year-old male presented with neck pain. Magnetic resonance imaging of the neck revealed a C3 vertebral body collapse and an underlying C3 lesion. Computed tomography (CT) of the thorax, abdomen, and pelvis showed multiple skeletal lesions, a sternal mass, bilateral pulmonary nodules, bilateral adrenal masses, and an aortocaval lymph node conglomerate. He underwent biopsy of the sternal mass, which revealed metastatic pheochromocytoma and subsequent blood work showed serum epinephrine levels of 200 pg/mL (normal 10-200 pg/mL), norepinephrine 28 241 pg/mL (normal 80-520 pg/mL), and dopamine 250 pg/mL (normal 0-20 pg/mL). Genetic testing revealed both SDHB and TP53 germline mutations. He was started on alpha- and beta-blockers and calcium channel blockers to control hypertension and tachycardia. Two months after the diagnosis, a CT of the abdomen and pelvis showed progression of disease, with enlargement of the right adrenal mass as well as the aortocaval conglomeration. His plasma metanephrines were significantly elevated. He was started on systemic chemotherapy with cyclophosphamide, dacarbazine, and vincristine. He required several antihypertensive agents, including metyrosine, to control his blood pressure in preparation for chemotherapy. Conclusion. This is the first reported case of simultaneous SDHB and TP53 germline mutations occurring in an individual with a highly aggressive clinical course of pheochromocytoma. We speculate that the simultaneous occurrence of these 2 oncogenic mutations may have led to an aggressive tumor progression.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [41] Impact of germline TP53 mutations and polymorphisms in women with premenopausal breast cancer
    Samuel, Nardin
    Novokmet, Ana
    Hudson, Thomas J.
    Malkin, David
    CANCER RESEARCH, 2014, 74 (23)
  • [42] GERMLINE TP53 MUTATIONS IN A COHORT OF PAEDIATRIC HYPODIPLOID ACUTE LYMPHOBLASTIC LEUKEMIA
    Bettini, L. R.
    Saitta, C.
    Buldini, B.
    Grioni, A.
    Rebellato, S.
    Silvestri, D.
    Biondi, A.
    Fazio, G.
    Cazzaniga, G.
    HAEMATOLOGICA, 2020, 105 : S89 - S89
  • [43] Germline Mutations of TP53 Gene Among Children with Cancer from Russia
    Yasko, L.
    Kurnikova, M.
    Mersiyanova, I.
    Brilliantova, V.
    Raikina, E.
    Druy, A.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S511 - S511
  • [44] Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
    Zhang, Wensheng
    Dong, Yan
    Sartor, Oliver
    Zhang, Kun
    CANCER INFORMATICS, 2022, 21
  • [45] Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
    Zhang, Wensheng
    Dong, Yan
    Sartor, Oliver
    Zhang, Kun
    CANCER INFORMATICS, 2022, 21
  • [46] Germline TP53 Variants and Susceptibility to Osteosarcoma
    Mirabello, Lisa
    Yeager, Meredith
    Mai, Phuong L.
    Gastier-Foster, Julie M.
    Gorlick, Richard
    Khanna, Chand
    Patino-Garcia, Ana
    Sierrasesumaga, Luis
    Lecanda, Fernando
    Andrulis, Irene L.
    Wunder, Jay S.
    Gokgoz, Nalan
    Barkauskas, Donald A.
    Zhang, Xijun
    Vogt, Aurelie
    Jones, Kristine
    Boland, Joseph F.
    Chanock, Stephen J.
    Savage, Sharon A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (07):
  • [47] Sarcomas in TP53 germline mutation carriers
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER RESEARCH, 2011, 71
  • [48] A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME
    Douglass, David
    Farrar, Jason
    Stine, Kimo
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [49] REMISSION OF AML IN A PATIENT WITH GERMLINE TP53 MUTATION AFTER DECITABINE MONOTHERAPY
    Sadanand, Arhanti
    Qayed, Muna
    Keller, Frank
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [50] TP53 mutations in myelodysplastic syndrome
    Misawa, S
    Horiike, S
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 417 - 422